Efficacy and Safety Assessments of a Peritoneal Dialysis Solution Containing Glucose, Xylitol, and L-Carnitine in CAPD

Stopped prematurely interrupted due to significant difficulties in the completion of the sample size defined by the study protocol

Conditions

• End Stage Renal Disease

Interventions

• DRUG: 1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine
• DRUG: 0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine

Sponsor

Iperboreal Pharma Srl